Retension Pharmaceuticals prices upsized IPO at $12 per share
- Retension Pharmaceuticals priced its IPO at $12.00 per share
- Gross proceeds expected to reach $45.0 million before fees
- Proceeds fund Phase 2b completion and Phase 3 prep for RTN-001
- Shares begin trading on Nasdaq as RTSN on October 9, 2026
*this image is generated using AI for illustrative purposes only.
Retension Pharmaceuticals (NASDAQ: RTSN) priced its upsized initial public offering of 3,750,000 shares at $12.00 per share, generating gross proceeds of $45.0 million. The clinical-stage biopharmaceutical company plans to list on the Nasdaq Capital Market under the ticker "RTSN" on October 9, 2026.
The offering includes a 30-day option for underwriters to purchase an additional 562,500 shares at the same price. The transaction is expected to close on or about October 13, 2026, subject to customary closing conditions. Leerink Partners, Guggenheim Securities, and Oppenheimer & Co. serve as joint bookrunning managers, while Titan Partners acts as lead manager.
Use of Proceeds and Pipeline Focus
Retension intends to deploy the net proceeds, alongside existing cash reserves, to advance its lead candidate, RTN-001. The funds will support the completion of the Phase 2b clinical trial in uncontrolled hypertension (uHTN) and prepare for the planned Phase 3 trial. Remaining capital is allocated to general corporate purposes and operating expenses.
RTN-001 is a cardiovascular-targeted, next-generation PDE5 inhibitor designed to enhance nitric oxide signaling in central arteries. The drug is being developed under an exclusive worldwide license from Sanofi S.A.
Clinical Data Overview
The company reports that RTN-001 has been studied in multiple clinical trials totaling 265 enrolled subjects. In two Phase 2 pilot trials, the candidate achieved clinically meaningful placebo-adjusted reductions in both systolic and diastolic blood pressure in patients with hypertension.
| Offering Detail | Value |
|---|---|
| Shares Offered | 3,750,000 |
| Price Per Share | $12.00 |
| Gross Proceeds | $45.0 million |
| Underwriter Option | 562,500 shares |
| Expected Listing Date | October 9, 2026 |
What the Numbers Show
The gross proceeds of $45.0 million represent the primary capital infusion for Retension's clinical development phase. When combined with the potential additional $6.75 million from the full exercise of the underwriters' option (562,500 shares at $12.00), the total potential gross raise reaches $51.75 million. This capital structure directly supports the dual-track strategy of completing Phase 2b trials while simultaneously preparing for Phase 3 initiation, indicating a focused allocation toward near-term regulatory milestones for RTN-001.
How will the $45.0 million in gross proceeds impact Retension's cash runway relative to the anticipated timeline for Phase 3 initiation?
What are the potential financial or strategic implications of the exclusive worldwide license from Sanofi if RTN-001 achieves commercial success?
How might the competitive landscape in uncontrolled hypertension treatments influence investor sentiment during RTSN's initial trading period?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
